Mosunetuzumab联合Polatuzumab Vedotin一线治疗老年不适合或衰弱的大B细胞淋巴瘤
这项多中心国际开放标签I/II期试验评估了皮下Mosunetuzumab联合Polatuzumab Vedotin一线治疗经简化老年评估(sGA)判定为不适合或衰弱的初治弥漫大B细胞淋巴瘤(DLBCL)患者。全剂量治疗组(n=101)中位年龄81岁,治疗结束时客观缓解率(ORR)为61.4%,完全缓解(CR)率56.4%,最佳ORR和CR率分别为80.2%和66.3%。中位随访36.5个月,中位缓解持续时间和总生存未达到,2年无进展生存和总生存分别为52.2%和62.4%。
要点
- 全剂量组治疗结束ORR 61.4%,CR率56.4%,最佳ORR 80.2%。
- 中位随访36.5个月,2年PFS 52.2%,2年OS 62.4%。
- 细胞因子释放综合征发生率30.6%,主要为1级。
核心结论
- 该老年评估指导的无化疗免疫治疗方案在经选择的初治不适合或衰弱DLBCL患者中显示出持久疗效,可能成为潜在的一线治疗选择。
研究设计与样本
- 多中心、国际、开放标签I/II期试验,纳入经简化老年评估(sGA)判定为不适合或衰弱的初治DLBCL患者。
- 全剂量治疗组共101例,中位年龄81岁,58%为不适合,41%为衰弱。
- 方案为6周期Polatuzumab Vedotin联合皮下Mosunetuzumab递增剂量,后续Mosunetuzumab单药治疗至计划总8周期。
- 主要终点为治疗结束时经独立评审采用PET-CT Lugano 2014标准评估的客观缓解率(ORR)。
主要发现
- 全剂量组治疗结束时ORR为61.4%(95% CI, 51.1-70.9),CR率为56.4%。
- 治疗期间最佳ORR和CR率分别为80.2%和66.3%。
- 中位随访36.5个月,中位研究者评估的缓解持续时间和总生存均未达到。
- 估计2年无进展生存率为52.2%,2年总生存率为62.4%。
- 细胞因子释放综合征发生率为30.6%,主要为1级;观察到感染相关死亡,主要发生于COVID-19疫情期间及衰弱患者中。
临床怎么用
- 对于经sGA评估为不适合或衰弱的初治DLBCL老年患者,可考虑该无化疗免疫方案作为潜在一线选择。
- 治疗期间需监测细胞因子释放综合征,多数为1级。
- 衰弱患者及疫情期间需警惕感染相关死亡风险。
局限性
- 为I/II期单臂试验,样本量有限(全剂量组n=101)。
- 感染相关死亡主要发生在COVID-19疫情期间,可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Older or medically unfit patients with diffuse large B-cell lymphoma (DLBCL) frequently cannot tolerate standard anthracycline-based immunochemotherapy, creating a persistent unmet clinical need. We conducted a multicenter, international, open-label phase I/II trial evaluating an immunotherapy-based first-line approach using subcutaneous mosunetuzumab in combination with polatuzumab vedotin in previously untreated patients classified as unfit or frail by simplified geriatric assessment (sGA). Participants received six cycles of polatuzumab vedotin with step-up-dosing of subcutaneous mosunetuzumab, followed by mosunetuzumab monotherapy for a planned total of eight cycles. The primary endpoint was objective response rate (ORR) at end of treatment, assessed by independent review using PET-CT Lugano 2014 criteria. Among participants treated at full dose (n=101), the median age was 81 years with 58% classified as unfit and 41% as frail by sGA. The ORR at the end of treatment was 61.4% (95% CI, 51.1-70.9), with a complete response (CR) rate of 56.4%. The best observed ORR and CR rates on therapy were 80.2% and 66.3%, respectively. With a median follow-up of 36.5 months, median investigator-assessed duration of response and overall survival were not reached; estimated 2-year progression-free and overall survival were 52.2% and 62.4%, respectively. Cytokine release syndrome occurred in 30.6% of participants and was predominantly grade 1. Infection-related mortality was observed, largely during the COVID-19 pandemic and among participants classified as frail. This geriatric assessment-guided treatment demonstrated durable efficacy and may represent a potential first-line treatment option for carefully selected unfit or frail patients with newly diagnosed DLBCL. Trial registration: #NCT03677154.
引用
- Olszewski AJ, Eradat HA, Avigdor A, et al. Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients. Blood. 2026. PMID: 42832423. doi:10.1182/blood.2026035116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。